Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection

E-ISSN： 1365-2036|42|3|258-272

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.42, Iss.3, 2015-08, pp. : 258-272

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The efficacy and safety of direct acting antiviral treatment and clinical significance of drug–drug interactions in elderly patients with chronic hepatitis C virus infection

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 44, Iss. 8, 2016-10 ,pp. : 856-865

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection

HEPATOLOGY, Vol. 67, Iss. 2, 2018-02 ,pp. : 505-513

John Wiley & Sons Inc

Access to resources Recommend Favorite

All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study

HEPATOLOGY, Vol. 61, Iss. 4, 2015-04 ,pp. : 1127-1135

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and Safety of Sofosbuvir in the Treatment of Chronic Hepatitis C: The Dawn of a New Era

Reviews on Recent Clinical Trials, Vol. 9, Iss. 1, 2014-03 ,pp. : 1-7

Bentham Science Publishers

Access to resources Recommend Favorite

Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 4, 2015-04 ,pp. : 366-375

John Wiley & Sons Inc

Access to resources Recommend Favorite